Analyst Price Targets — KROS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| November 5, 2024 6:47 pm | Kelly Shi | Jefferies | $107.00 | $62.02 | StreetInsider | Jefferies Starts Keros Therapeutics (KROS) at Buy |
| November 5, 2024 11:06 am | Srikripa Devarakonda | Truist Financial | $100.00 | $62.02 | StreetInsider | Truist Securities Reiterates Buy Rating on Keros Therapeutics (KROS) |
| September 23, 2024 2:57 am | Vamil Divan | Guggenheim | $96.00 | $55.80 | StreetInsider | Guggenheim Starts Keros Therapeutics (KROS) at Buy |
| June 18, 2024 7:57 am | Joseph Catanzaro | Piper Sandler | $105.00 | $44.65 | StreetInsider | Piper Sandler Reiterates Overweight Rating on Keros Therapeutics (KROS) |
| December 13, 2022 8:49 am | — | BTIG | $105.00 | $49.98 | Benzinga | BTIG Maintains Buy on Keros Therapeutics, Raises Price Target to $105 |
| July 27, 2022 7:59 pm | Julian Harrison | BTIG | $80.00 | $31.79 | Pulse 2.0 | Keros Therapeutics (KROS) Stock: Why It Surged 11.43% Today |
| May 18, 2022 10:06 am | Joseph Catanzaro | Piper Sandler | $120.00 | $39.92 | TheFly | Keros Therapeutics price target raised to $120 from $90 at Piper Sandler |
Latest News for KROS
LEXINGTON, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced the appointment of…
Keros Therapeutics, Inc. (KROS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
LEXINGTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that Keros' President and Chief…
Keros faces a volatile setup after its Q1 miss, with a longer cash runway and leaner costs balanced against uncertain milestone-driven revenue.
Keros is shifting toward rinvatercept-led neuromuscular development, with phase II plans, early human signals and cash runway shaping the KROS story.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for KROS.
U.S. House Trading
No House trades found for KROS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.